Monitor the pace and pricing of stock sales under this ATM offering, as frequent sales could signal cash burn concerns and may pressure the stock price. Watch for any updates on the use of proceeds, especially regarding the progress of their clinical trials.
Price Chart
Executive Summary
AN2 Therapeutics has filed a $80 million at-the-market (ATM) offering through Jefferies, allowing it to sell common stock from time to time. The offering is part of a shelf registration that replaces an expiring one, with proceeds intended for R&D and general corporate purposes. This follows a recent $40 million private placement.
Key Facts
- AN2 Therapeutics filed a $80 million at-the-market (ATM) offering through Jefferies.
- The offering is part of a shelf registration that replaces an expiring one.
- Proceeds from the offering are intended for research and development and general corporate purposes.
- This follows a recent $40 million private placement.
- The company's stock is listed on the Nasdaq Global Select Market under the symbol ANTX.
Financial Impact
The offering could raise up to $80 million, with proceeds primarily used for R&D and general corporate purposes.
Risk Factors
- Dilution to existing shareholders as new shares are issued.
- Potential downward pressure on the stock price due to increased supply in the market.
- The company may not use the proceeds effectively, which could negatively impact its financial condition and market value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-164095 |
| Document: 0001193125-26-164095-index-headers.html | 0001193125-26-164095 |
| Document: 0001193125-26-164095-index.html | 0001193125-26-164095 |
| Document: 0001193125-26-164095.txt | 0001193125-26-164095 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $6.28 | awaiting T+60 | — | $3.63 (−42.20%) |
Jun 4, 2026 20w ago | 8-K | $3.82 $5.55 | ▲ +45.29% | ▲ +41.29% | $3.63 (−4.97%) |
Apr 22, 2026 26w ago | DEFA14A | $4.28 $4.80 | ▲ +12.15% | ▲ +7.13% | $3.63 (−15.19%) |
Apr 21, 2026 26w ago | EFFECT | $3.80 $4.67 | ▲ +22.89% | ▲ +16.00% | $3.63 (−4.47%) |
Apr 20, 2026 27w ago | 424B5 | $3.80 $4.67 | ▼ −22.89% | ▼ −16.00% | $3.63 (+4.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers